title: Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule.
abstract: Oxidative stress (OS) is thought to participate in neurodegenerative diseases such as Parkinson's disease, but the contribution of dopamine metabolism and auto-oxidation to OS in Parkinson's and other diseases is not clear. Oxidative stress in rat striatum was measured by microdialysis using a novel synthetic compound composed of tyrosine and linoleic acid (LT), and determination of the oxidation products LT-OOH and LT-epoxy by HPLC-MS. Since LT is non-diffusible through the microdialysis membrane, the oxidized products formed in microdialyzate reflect oxidation state in the extracellular compartment. The extracellular oxidative stress (OS(ec)) was compared with intracellular oxidative stress (OS(ic)) as measured by tissue levels of oxidized and reduced glutathione and 7-ketocholesterol. Reserpinization caused an increase in OS(ic) but a reduction in OS(ec). Inhibition of both subtypes of monoamine oxidase (MAO-A and MAO-B) with tranylcypromine caused a reduction in both OS(ic) and OS(ec) whereas selective inhibition of MAO-A with clorgyline caused a reduction in Os(ic) but no change in OS(ec). A high dose (10 mg/kg) of amphetamine caused an increase in OS(ec) whereas a smaller dose (4 mg/kg) caused a reduction in OS(ec). Both doses of amphetamine reduced OS(ic). The present findings are consistent with a role of monoamine oxidase as well as dopamine auto-oxidation in production of striatal OS.
authors.affiliation: Department of Molecular Pharmacology, Rappaport Medical Faculty, Technion, Haifa, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Aluf
authors.forename: J
authors.initials: J
authors.lastname: Vaya
authors.forename: S
authors.initials: S
authors.lastname: Khatib
authors.forename: J P M
authors.initials: JP
authors.lastname: Finberg
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D019787:Linoleic Acid / Q000378:metabolism*; D008297:Male; D017551:Microdialysis / Q000379:methods; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014443:Tyrosine / Q000378:metabolism*
chemical_list: D000975:Antioxidants; D008996:Monoamine Oxidase Inhibitors; D014443:Tyrosine; D019787:Linoleic Acid; D004298:Dopamine